Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers
<b>Background</b>: Psoriasis is a skin disease characterized by the presence of erythematous, scaly plaques on the extensor surfaces of the body. Treatment varies according to the stage of the disease, with the most severe cases being treated with biologic treatments that differ in effic...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589062971588608 |
|---|---|
| author | Andrea Rodríguez-Lopez María Martínez-Sendino Rocío Prieto-Pérez Paula Soria-Chacartegui Eva González-Iglesias Mario Aparicio-Domínguez Sonsoles Berenguer-Ruiz Esteban Daudén Francisco Abad-Santos |
| author_facet | Andrea Rodríguez-Lopez María Martínez-Sendino Rocío Prieto-Pérez Paula Soria-Chacartegui Eva González-Iglesias Mario Aparicio-Domínguez Sonsoles Berenguer-Ruiz Esteban Daudén Francisco Abad-Santos |
| author_sort | Andrea Rodríguez-Lopez |
| collection | DOAJ |
| description | <b>Background</b>: Psoriasis is a skin disease characterized by the presence of erythematous, scaly plaques on the extensor surfaces of the body. Treatment varies according to the stage of the disease, with the most severe cases being treated with biologic treatments that differ in efficacy and persistence over time. This study aimed to evaluate the 10-year persistence of biologic drugs (adalimumab, etanercept, infliximab and ustekinumab) in the treatment of moderate-to-severe plaque psoriasis. <b>Methods</b>: A total of 143 patients (61 women and 82 men) were evaluated; data were collected from the electronic clinical history, and statistical analysis was performed using the SPSS program. In addition, 115 of them were genotyped in a previous study for 173 immune system genetic polymorphisms. <b>Results</b>: The persistence of biologic drugs at 10 years was 25.9% (95% CI: 17.2–34.5%). Adalimumab was the most persistent drug (41.5%), followed by ustekinumab (34.8%), infliximab (28%) and etanercept (9.3%). The main reason for discontinuation was insufficient efficacy (51%). Adalimumab allowed an increase in the dosing interval in 82.4% of patients who persisted and ustekinumab allowed an increase in 37.5%. The 10-year persistence was related to sex (higher in men, <i>p</i> < 0.001), biologic drug (<i>p</i> = 0.002) and polymorphisms in <i>LMO4</i> (rs983332) (<i>p</i> = 0.014) and <i>IL20RA</i> (rs1167846) (<i>p</i> = 0.013). <b>Conclusion</b>: The results show that 25% of psoriasis patients treated with first-line biologics persisted at 10 years. |
| format | Article |
| id | doaj-art-9d701bb1675649db85f6d77a391d9634 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-9d701bb1675649db85f6d77a391d96342025-01-24T13:23:41ZengMDPI AGBiomedicines2227-90592024-12-01131510.3390/biomedicines13010005Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic BiomarkersAndrea Rodríguez-Lopez0María Martínez-Sendino1Rocío Prieto-Pérez2Paula Soria-Chacartegui3Eva González-Iglesias4Mario Aparicio-Domínguez5Sonsoles Berenguer-Ruiz6Esteban Daudén7Francisco Abad-Santos8Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, SpainClinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, SpainClinical Pharmacology Department, Hospital Universitario La Paz, Department of Pharmacology and Therapeutics, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), IdiPAZ, 28046 Madrid, SpainClinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, SpainClinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, SpainDermatology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, SpainDermatology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, SpainDermatology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, SpainClinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, Spain<b>Background</b>: Psoriasis is a skin disease characterized by the presence of erythematous, scaly plaques on the extensor surfaces of the body. Treatment varies according to the stage of the disease, with the most severe cases being treated with biologic treatments that differ in efficacy and persistence over time. This study aimed to evaluate the 10-year persistence of biologic drugs (adalimumab, etanercept, infliximab and ustekinumab) in the treatment of moderate-to-severe plaque psoriasis. <b>Methods</b>: A total of 143 patients (61 women and 82 men) were evaluated; data were collected from the electronic clinical history, and statistical analysis was performed using the SPSS program. In addition, 115 of them were genotyped in a previous study for 173 immune system genetic polymorphisms. <b>Results</b>: The persistence of biologic drugs at 10 years was 25.9% (95% CI: 17.2–34.5%). Adalimumab was the most persistent drug (41.5%), followed by ustekinumab (34.8%), infliximab (28%) and etanercept (9.3%). The main reason for discontinuation was insufficient efficacy (51%). Adalimumab allowed an increase in the dosing interval in 82.4% of patients who persisted and ustekinumab allowed an increase in 37.5%. The 10-year persistence was related to sex (higher in men, <i>p</i> < 0.001), biologic drug (<i>p</i> = 0.002) and polymorphisms in <i>LMO4</i> (rs983332) (<i>p</i> = 0.014) and <i>IL20RA</i> (rs1167846) (<i>p</i> = 0.013). <b>Conclusion</b>: The results show that 25% of psoriasis patients treated with first-line biologics persisted at 10 years.https://www.mdpi.com/2227-9059/13/1/5psoriasispersistencebiologic therapiesloss of efficacypharmacogenetic biomarkers |
| spellingShingle | Andrea Rodríguez-Lopez María Martínez-Sendino Rocío Prieto-Pérez Paula Soria-Chacartegui Eva González-Iglesias Mario Aparicio-Domínguez Sonsoles Berenguer-Ruiz Esteban Daudén Francisco Abad-Santos Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers Biomedicines psoriasis persistence biologic therapies loss of efficacy pharmacogenetic biomarkers |
| title | Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers |
| title_full | Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers |
| title_fullStr | Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers |
| title_full_unstemmed | Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers |
| title_short | Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers |
| title_sort | ten year persistence of biologic drugs in psoriasis and its relationship with pharmacogenetic biomarkers |
| topic | psoriasis persistence biologic therapies loss of efficacy pharmacogenetic biomarkers |
| url | https://www.mdpi.com/2227-9059/13/1/5 |
| work_keys_str_mv | AT andrearodriguezlopez tenyearpersistenceofbiologicdrugsinpsoriasisanditsrelationshipwithpharmacogeneticbiomarkers AT mariamartinezsendino tenyearpersistenceofbiologicdrugsinpsoriasisanditsrelationshipwithpharmacogeneticbiomarkers AT rocioprietoperez tenyearpersistenceofbiologicdrugsinpsoriasisanditsrelationshipwithpharmacogeneticbiomarkers AT paulasoriachacartegui tenyearpersistenceofbiologicdrugsinpsoriasisanditsrelationshipwithpharmacogeneticbiomarkers AT evagonzaleziglesias tenyearpersistenceofbiologicdrugsinpsoriasisanditsrelationshipwithpharmacogeneticbiomarkers AT marioapariciodominguez tenyearpersistenceofbiologicdrugsinpsoriasisanditsrelationshipwithpharmacogeneticbiomarkers AT sonsolesberenguerruiz tenyearpersistenceofbiologicdrugsinpsoriasisanditsrelationshipwithpharmacogeneticbiomarkers AT estebandauden tenyearpersistenceofbiologicdrugsinpsoriasisanditsrelationshipwithpharmacogeneticbiomarkers AT franciscoabadsantos tenyearpersistenceofbiologicdrugsinpsoriasisanditsrelationshipwithpharmacogeneticbiomarkers |